AVTX

Avalo Therapeutics Inc

18.20

Jun 26 • 04:00PM ET +0.20 (1.11%)

Healthcare Biotechnology USA Small NASD

Today, 7:35 AMAvalo Therapeutics announces it will be added to the Russell 2000 and Russell 3000 indexes effective after the close of trading on June 26, 2026.

Peers: KYMR NUVL RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: XBI VTI VXF IWC ITOT LABU TMSL BBC DFAS DFMC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.82	Insider Own	8.98%	Shs Outstand	52.57M	Perf Week	23.81%
Market Cap	956.69M	Forward P/E	-	EPS next Y	-3.03	Insider Trans	-6.35%	Shs Float	47.84M	Perf Month	15.26%
Enterprise Value	876.88M	PEG	-	EPS next Q	-0.62	Inst Own	76.36%	Short Float	15.50%	Perf Quarter	30.47%
Income	-84.74M	P/S	15944.89	EPS this Y	47.12%	Inst Trans	21.91%	Short Ratio	4.26	Perf Half Y	-2.52%
Sales	0.06M	P/B	6.56	EPS next Y	1.73%	ROA	-71.09%	Short Interest	7.41M	Perf YTD	0.22%
Book/sh	2.77	P/C	11.65	EPS next 5Y	21.15%	ROE	-88.76%	52W High	24.27 -25.01%	Perf Year	282.35%
Cash/sh	1.56	P/FCF	-	EPS past 3/5Y	82.35% 70.20%	ROIC	-120.51%	52W Low	4.53 301.77%	Perf 3Y	-84.83%
Dividend Est.	0.01 (0.06%)	EV/EBITDA	-	Sales past 3/5Y	-85.16% -61.19%	Gross Margin	-283.05%	Volatility	8.45% 7.32%	Perf 5Y	-99.82%
Dividend TTM	-	EV/Sales	14614.72	EPS Y/Y TTM	-1121.44%	Oper. Margin	-134164.41%	ATR (14)	1.19	Perf 10Y	-99.74%
Dividend Ex-Date	-	Quick Ratio	7.66	Sales Y/Y TTM	-86.62%	Profit Margin	-143627.12%	RSI (14)	64.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.66	EPS Q/Q	21.93%	SMA20	20.70%	Beta	0.77	Target Price	45.25
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	14.78%	Rel Volume	4.92	Prev Close	18.00
Employees	33	LT Debt/Eq	0.03	Earnings	May 13 BMO	SMA200	15.69%	Avg Volume	1.74M	Price	18.20
IPO	Nov 13, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.42% -	Trades		Volume	8,560,612	Change	1.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-26	Initiated	BofA Securities	Buy	$35
Apr-09-26	Initiated	Wolfe Research	Outperform	$48
Apr-06-26	Initiated	Citizens	Mkt Outperform	$52
Feb-02-26	Initiated	Guggenheim	Buy	$50
Dec-18-25	Initiated	Mizuho	Outperform	$39
Sep-17-25	Reiterated	H.C. Wainwright	Buy	$15 → $25
Sep-05-25	Initiated	TD Cowen	Buy
Aug-15-25	Initiated	Cantor Fitzgerald	Overweight
Jun-02-25	Resumed	H.C. Wainwright	Buy	$15
Mar-25-25	Initiated	Stifel	Buy	$36
Mar-25-25	Initiated	Jefferies	Buy	$23
Feb-28-25	Initiated	Piper Sandler	Overweight	$48
Feb-21-25	Initiated	Wedbush	Outperform	$18
Dec-19-24	Initiated	BTIG Research	Buy	$40
Oct-24-24	Initiated	H.C. Wainwright	Neutral
Apr-16-24	Upgrade	Oppenheimer	Perform → Outperform	$35
Sep-24-21	Initiated	RBC Capital Mkts	Outperform	$6

Show Previous Ratings

Today 07:00AM	Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-23-26 07:00AM	Avalo Therapeutics Appoints Ron Philip to Board of Directors (GlobeNewswire)
Jun-16-26 07:00AM	Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1ß Antibody (GlobeNewswire)
May-22-26 04:01PM	Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-26 07:00AM	Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates (GlobeNewswire)
06:30AM	Loading…
May-06-26 06:30AM	Avalo shares spike on skin drug data; BioNTech to cut staff (BioPharma Dive) +34.13%
May-05-26 11:33PM	Avalo Therapeutics Announces Pricing of $375 Million Public Offering (GlobeNewswire) +18.00%
04:05PM	Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa (GlobeNewswire)
Apr-28-26 07:00AM	Avalo Therapeutics Purchases Optional Milestone Buyout (GlobeNewswire) -10.82%
Apr-03-26 08:00PM	Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know (Quartz)
Mar-23-26 07:00AM	Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Mar-05-26 07:07AM	Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference (MarketBeat)
Feb-25-26 08:06PM	Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference (MarketBeat)
Feb-24-26 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.46%
04:05PM	Loading…
Feb-18-26 04:05PM	Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.47%
Feb-11-26 06:39PM	Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa (MarketBeat)
Feb-04-26 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.96%
Feb-02-26 02:25PM	Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case (Benzinga)
Nov-17-25 04:30PM	Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.68% +6.67%
Nov-06-25 07:00AM	Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire) -6.26%
Nov-03-25 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.54%
Oct-29-25 11:57AM	Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) (Insider Monkey)
07:00AM	Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa (GlobeNewswire)
Oct-01-25 07:00AM	Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources (GlobeNewswire)
Sep-22-25 07:00AM	Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors (GlobeNewswire)
Aug-27-25 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 07:00AM	Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Jul-02-25 10:03PM	Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances (Insider Monkey)
07:00AM	Loading…
Jun-23-25 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-18-25 07:00AM	Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors (GlobeNewswire) +6.49%
May-27-25 10:05AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 07:00AM	Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire)
Apr-30-25 07:00AM	Avalo Therapeutics to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-20-25 07:00AM	Avalo Reports 2024 Financial Results and Recent Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-04-25 08:00AM	Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-02-25 07:00AM	Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer (GlobeNewswire) +13.46%
Dec-20-24 06:50AM	Avalo Therapeutics initiated with a Buy at BTIG (TipRanks)
Nov-12-24 07:00AM	Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants (GlobeNewswire)
Nov-11-24 07:00AM	Avalo Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 07:00AM	Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-08-24 07:00AM	Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa (GlobeNewswire)
Sep-04-24 07:00AM	Avalo Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-24 07:00AM	Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -7.30%
Jul-16-24 07:00AM	Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer (GlobeNewswire)
Jul-09-24 07:00AM	Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa (GlobeNewswire)
Jun-24-24 04:01PM	Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer (GlobeNewswire)
Jun-17-24 07:30AM	Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
May-24-24 01:52PM	AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +17.49%
May-22-24 09:40AM	Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
May-13-24 03:52PM	AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:30AM	Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-24 11:30AM	Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why (Zacks) -15.31%
07:00AM	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-29-24 04:01PM	Avalo Reports 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-28-24 08:04AM	Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today? (InvestorPlace) +357.89%
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
10:00AM	Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-26-24 11:28AM	Avalo (AVTX) to Report Q4 Earnings: What's in the Cards? (Zacks)
Dec-27-23 07:00AM	Avalo Therapeutics Announces 1-for-240 Reverse Stock Split (GlobeNewswire)
Dec-07-23 07:00AM	Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split (GlobeNewswire) -5.61%
Nov-09-23 07:00AM	Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -10.09%
Oct-31-23 07:00AM	Avalo Completes Divestiture of AVTX-800 Series (GlobeNewswire) +18.00%
Sep-27-23 08:00AM	BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics (News Direct) +12.19%
Sep-26-23 07:00AM	Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation (GlobeNewswire) -7.36%
Sep-12-23 07:00AM	Avalo Enters into Agreement to Divest AVTX-800 Series (GlobeNewswire) +45.47%
Sep-06-23 07:00AM	Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 07:00AM	Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-06-23 04:01PM	Avalo to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 07:00AM	Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma (GlobeNewswire) -88.69%
Jun-01-23 07:00AM	Avalo to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 07:00AM	Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board (GlobeNewswire) -11.76%
May-15-23 07:00AM	Avalo to Present at ATS 2023 Respiratory Innovation Summit (GlobeNewswire) +11.79%
May-10-23 07:00AM	Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-04-23 04:01PM	Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -5.37% -7.80%
Mar-29-23 07:30AM	Avalo Reports 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.47%
Mar-07-23 07:00AM	Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-02-23 09:54PM	Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
04:01PM	Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
Jan-17-23 07:00AM	Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma (GlobeNewswire)
Nov-07-22 07:30AM	Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million (GlobeNewswire)
Sep-06-22 07:00AM	Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage (GlobeNewswire) +22.29%
Sep-01-22 07:00AM	Avalo to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Avalo Therapeutics Announces Board Changes (GlobeNewswire) +6.06%
Aug-09-22 10:39AM	These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer (TipRanks) +32.14%
Aug-04-22 07:30AM	Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.96%
Aug-02-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) (GlobeNewswire)
Aug-01-22 07:00AM	Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics (GlobeNewswire)
Jul-06-22 04:05PM	Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split (GlobeNewswire) -20.97%
Jun-20-22 12:10PM	Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-02-22 07:30AM	Avalo to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-18-22 07:30AM	Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) (GlobeNewswire) +6.82%
May-17-22 07:30AM	Avalo to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) +15.08%
May-05-22 07:30AM	Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.27%

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

PresidentDr. Garry A. Neil M.D.

M.D.Dr. Mittie Doyle FACR

Chief Business OfficerMr. Taylor Boyd

Founder and Chairman of Scientific Advisory BoardDr. Solomon H. Snyder M.D.

Founder and Member of Scientific Advisory BoardDr. Barbara S. Slusher Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Doyle Mittie	Chief Medical Officer	Jun 23 '26	Option Exercise	8.04	1,450	11,658	53,226	Jun 25 05:24 PM
Doyle Mittie	Chief Medical Officer	Jun 23 '26	Sale	18.00	1,450	26,100	51,776	Jun 25 05:24 PM
JONATHAN GOLDMAN	Director	Jun 02 '26	Proposed Sale	14.39	42,833	616,226		Jun 02 04:08 PM
Doyle Mittie	Chief Medical Officer	May 28 '26	Option Exercise	8.04	679	5,459	47,801	Jun 01 04:05 PM
Doyle Mittie	Chief Medical Officer	May 28 '26	Sale	16.00	679	10,864	47,122	Jun 01 04:05 PM
Doyle Mittie	Chief Medical Officer	May 15 '26	Option Exercise	12.65	3,000	37,950	6,622	May 19 04:10 PM
Doyle Mittie	Chief Medical Officer	May 15 '26	Sale	18.76	3,000	56,280	3,622	May 19 04:10 PM
Sullivan Christopher Ryan	Chief Financial Officer	May 07 '26	Option Exercise	9.88	18,606	183,827	19,029	May 11 04:05 PM
Sullivan Christopher Ryan	Chief Financial Officer	May 07 '26	Sale	24.12	18,606	448,818	423	May 11 04:05 PM
CHRISTOPHER SULLIVAN	Officer	May 07 '26	Proposed Sale	21.81	18,606	405,797		May 07 04:20 PM
VARKI PAUL	Chief Legal Officer	May 06 '26	Option Exercise	12.53	75,063	940,382	78,697	May 07 04:18 PM
VARKI PAUL	Chief Legal Officer	May 06 '26	Sale	20.17	75,063	1,513,673	3,634	May 07 04:18 PM
Sullivan Christopher Ryan	Chief Financial Officer	May 06 '26	Option Exercise	8.04	47,000	377,880	47,423	May 07 04:16 PM
Sullivan Christopher Ryan	Chief Financial Officer	May 06 '26	Sale	20.19	47,000	948,722	423	May 07 04:16 PM
Doyle Mittie	Chief Medical Officer	May 06 '26	Option Exercise	11.41	106,555	1,215,844	110,177	May 07 04:16 PM
Doyle Mittie	Chief Medical Officer	May 05 '26	Option Exercise	10.79	1,679	18,109	5,301	May 07 04:16 PM
Doyle Mittie	Chief Medical Officer	May 06 '26	Sale	20.68	106,555	2,203,503	3,622	May 07 04:16 PM
Doyle Mittie	Chief Medical Officer	May 05 '26	Sale	16.00	1,679	26,864	3,622	May 07 04:16 PM
Chan Mitchell	Director	May 06 '26	Sale	22.88	3,167	72,461	3,166	May 07 04:15 PM
MITTIE DOYLE	Officer	May 06 '26	Proposed Sale	16.26	54,508	886,300		May 06 04:54 PM
CHRISTOPHER SULLIVAN	Officer	May 06 '26	Proposed Sale	16.26	47,000	764,220		May 06 04:32 PM
PAUL VARKI	Officer	May 06 '26	Proposed Sale	16.26	92,771	1,508,456		May 06 04:30 PM
MITCHELL CHAN	Director	May 06 '26	Proposed Sale	16.26	3,167	51,495		May 06 04:29 PM
Sullivan Christopher Ryan	Chief Financial Officer	Apr 30 '26	Sale	13.23	8,457	111,853	423	May 01 04:37 PM
Sullivan Christopher Ryan	Chief Financial Officer	Apr 29 '26	Sale	13.09	8,458	110,736	8,880	May 01 04:37 PM
CHRISTOPHER SULLIVAN	Officer	Apr 29 '26	Proposed Sale	12.86	16,915	217,527		Apr 29 04:33 PM
Doyle Mittie	Chief Medical Officer	Apr 06 '26	Option Exercise	12.65	3,970	50,220	7,592	Apr 08 04:51 PM
Doyle Mittie	Chief Medical Officer	Apr 06 '26	Sale	18.01	3,970	71,508	3,622	Apr 08 04:51 PM
MITTIE DOYLE	Officer	Apr 06 '26	Proposed Sale	17.76	65,800	1,168,608		Apr 06 04:34 PM
Sullivan Christopher Ryan	Chief Financial Officer	Apr 02 '26	Sale	17.15	7,980	136,823	17,338	Apr 03 03:14 PM
Sullivan Christopher Ryan	Chief Financial Officer	Apr 01 '26	Sale	16.77	7,979	133,770	25,318	Apr 03 03:14 PM
Doyle Mittie	Chief Medical Officer	Apr 01 '26	Option Exercise	8.04	679	5,459	4,301	Apr 03 03:13 PM
Doyle Mittie	Chief Medical Officer	Apr 01 '26	Sale	16.00	679	10,864	3,622	Apr 03 03:13 PM
CHRISTOPHER SULLIVAN	Officer	Apr 01 '26	Proposed Sale	14.93	15,959	238,268		Apr 01 04:48 PM
Doyle Mittie	Chief Medical Officer	Mar 16 '26	Option Exercise	11.57	25,492	294,851	29,114	Mar 18 04:07 PM
Doyle Mittie	Chief Medical Officer	Mar 16 '26	Sale	16.15	25,492	411,607	3,622	Mar 18 04:07 PM
MITTIE DOYLE	Officer	Mar 16 '26	Proposed Sale	15.80	29,529	466,558		Mar 16 04:39 PM
Goldman Jonathan	Director	Nov 14 '25	Option Exercise	9.88	8,200	81,016	8,200	Nov 17 04:05 PM
Goldman Jonathan	Director	Nov 14 '25	Sale	14.33	11,367	162,937	0	Nov 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVTX

Avalo Therapeutics Inc

Upgrade your Finviz experience